Mainly because CCL5-CCR5 binding exerts tumor-stimulating effects (e.g., proliferation and production of tumor inflammatory cytokines) in mCRC, it is possible to antagonize metastatic tumors by means of CCR5 blockade (Table 1 NO.11). The gene discussed is CCL5; the disease is neoplasm.